FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
Feed Update Issues
We're having trouble fetching new episodes from this podcast's RSS feed. Last successful update was 2025-12-27 18:26:26.638618. This podcast may be geo-restricted.
Episodes
FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma
12 Mar 2019
Contributed by Lukas
FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma FDA medical oncologists discuss the January 14, 2019, approval of cabozanti...
FDA D.I.S.C.O.: FDA approval of larotrectinib for advanced malignancies with NTRK gene fusion
13 Dec 2018
Contributed by Lukas
FDA medical oncologists discuss the accelerated approval of larotrectinib for adult and pediatric patients with solid tumors that have a neurotrophic ...
FDA D.I.S.C.O.: FDA approval of cemiplimab-rwlc for cutaneous squamous cell carcinoma
30 Nov 2018
Contributed by Lukas
FDA medical oncologists discuss the September 28, 2018, approval of cemiplimab-rwlc for the treatment of select patients with cutaneous squamous cell ...
FDA D.I.S.C.O.: FDA approval of moxetumomab pasudotox-tdfk for relapsed or refractory hairy cell leukemia
29 Nov 2018
Contributed by Lukas
FDA medical oncologists discuss the Sept. 13, 2018, approval of moxetumomab pasudotox-tdfk for the treatment of patients with relapsed or refractory h...
FDA D.I.S.C.O.: A new drug approval for IDH1 positive relapsed or refractory Acute Myeloid Leukemia
15 Nov 2018
Contributed by Lukas
FDA medical oncologists discuss the July 2018 approval of ivosidenib for the treatment of patients with relapsed or refractory acute myeloid leukemia ...
FDA D.I.S.C.O.: Olaparib for gBRCAm HER2-negative metastatic breast cancer
23 Oct 2018
Contributed by Lukas
FDA medical oncologists discuss the January 12, 2018, approval of olaparib, the first PARP inhibitor approved for the treatment of patients with metas...
FDA D.I.S.C.O.: A supplemental drug approval for the adjuvant treatment of high risk advanced renal cell cancer - Transcript
16 Aug 2018
Contributed by Lukas
FDA medical oncologists discuss the November 2017 approval of sunitinib for the adjuvant treatment of patients with renal cell carcinoma who are at hi...
FDA D.I.S.C.O.: A new drug approval for non-metastatic castration-resistant prostate cancer
03 May 2018
Contributed by Lukas
FDA D.I.S.C.O.: A new drug approval for non-metastatic castration-resistant prostate cancer
FDA D.I.S.C.O.: Nivolumab for adjuvant treatment of patients with melanoma
26 Feb 2018
Contributed by Lukas
FDA medical oncologists discuss the December 20, 2017, approval of nivolumab for the adjuvant treatment of patients with melanoma.
FDA D.I.S.C.O.: First FDA approval of a CAR T-cell immunotherapy
23 Feb 2018
Contributed by Lukas
FDA medical oncologists discuss the first approval of a chimeric antigen receptor (CAR) T-cell immunotherapy.
FDA D.I.S.C.O.: First biosimilar approval for the treatment of cancer
21 Dec 2017
Contributed by Lukas
FDA D.I.S.C.O.: First biosimilar approval for the treatment of cancer FDA medical oncologists discuss the Sept 14, 2017, approval of MVASI, the first ...
FDA D.I.S.C.O.: A new treatment for acute myelogenous leukemia
15 Sep 2017
Contributed by Lukas
FDA D.I.S.C.O.: A new treatment for acute myelogenous leukemia FDA medical oncologists discuss the Aug. 3, 2017, approval of Vyxeos for treatment of a...
FDA D.I.S.C.O.: L-glutamine for sickle cell disease
18 Aug 2017
Contributed by Lukas
FDA D.I.S.C.O.: L-glutamine for sickle cell disease. FDA medical oncologists discuss the July 7, 2017, approval of l-glutamine to reduce the acute com...
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
28 Jul 2017
Contributed by Lukas
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-...
FDA D.I.S.C.O.: Two approvals for ALK-positive non-small cell lung cancer
25 Jul 2017
Contributed by Lukas
FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer.
FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval Transcript
30 May 2017
Contributed by Lukas
The D.I.S.C.O. hosts discuss the agency’s first approval of a cancer treatment based on a common biomarker rather than the location in the body wher...
FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma Transcript
22 May 2017
Contributed by Lukas
FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma FDA medical oncologists discuss the agency’s March 23, 2017, approval of avelumab the treatment of...
FDA D.I.S.C.O.: Niraparib in Ovarian Cancer Transcript
18 May 2017
Contributed by Lukas
FDA medical oncologists discuss the agency’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ov...
FDA D.I.S.C.O.: Niraparib in Ovarian Cancer
18 May 2017
Contributed by Lukas
FDA medical oncologists discuss the agency’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ov...
FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur
17 May 2017
Contributed by Lukas
FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur In our inaugural podcast, Dr. Richard Pazdur, director of the FDA Oncology Center of Excellence, talks wi...
FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
17 May 2017
Contributed by Lukas
FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer FDA medical oncologists discuss the agency’s December 2016 accelerated approval of rucaparib for treatme...